Build A Bear Workshop Inc vs Heron Therapeutics Inc — how do they compare? Build A Bear Workshop Inc trades at $36.88 (market cap $467.15M), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Build A Bear Workshop Inc is far larger — about 7.4× Heron Therapeutics Inc's market cap, and Build A Bear Workshop Inc pays a 2.47% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BBW | HRTX | |
|---|---|---|
Market Cap | $467.15M | $63.41M |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $1.49 |
52-Week Low | $29.84 | $0.32 |
Enterprise Value | $566.59M | $161.31M |
Dividend Yield | 2.47% | — |
Signals from Pluang's Aura AI — not financial advice
Build-A-Bear Workshop (BBW) trades at $36.86, up 6.19% today, with a bullish technical signal and strong analyst support. The stock exhibits attractive valuation metrics, including a P/E of 8.73 and P/S of 0.92, alongside robust profitability with a 10.48% net income margin and 35.87% ROE. Recent earnings have consistently beaten estimates, and the company maintains a debt-free balance sheet while executing a growth strategy focused on international expansion and brand partnerships.
The outlook for BBW is positive, driven by earnings momentum and a consensus price target of $62.50 implying significant upside. Key risks include near-term consumer spending volatility and execution of expansion plans, but strong fundamentals and shareholder returns via dividends support a favorable risk-reward profile for long-term investors.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →